We are currently investigating new medicine that may help lower Cholesterol (and improve outcomes), and in some cases these agents are specifically helpful for lowering elevated Triglyceride (TG) levels. These investigational agents are unique in action and different from the widely used statin drugs.
The main qualifying criteria and a brief synopsis of each of these studies is as follows. If you would like to consider participating, please click on the questionnaire link and complete it, and we will be happy to discuss this further with you. The following are ongoing clinical trials:
AEGIS II: Recent myocardial infarction
VESALIUS: To assess the effect of lowering LDL-C with Evolocumab on major CV events in adults at high CV risk without prior MI or Stroke
Interested in hearing more about the current studies? Wondering if you qualify to participate? Contact us using the link below and the research team will get back to you soon!
Completed Studies (Not currently recruiting)
FOURIER: Outcomes trial of PCSK9 blocking MoAb (injection every 2 weeks or every 4 weeks); must be able to take a statin and have established cardiovascular disease (previous Heart Attack, Stroke, or Peripheral Vascular Disease)
ODYSSEY: Outcomes trial of a PCSK9 blocking MoAb (injection every 2 weeks) in patients who have had a Heart Attack (or Unstable Angina - chest pain at rest due to a blocked coronary artery) within the last 1 year.
SPIRE: Outcomes trial of PCSK9 blocking MoAb (injection every 2 weeks or every 4 weeks) in patients at high cardiovascular risk - established heart or vascular blockage, diabetes or other high risk features.
COMPASS: for patients with very high Triglyceride levels (over 500 mg/dL) in which an ASO injection medicine given once a week will be studied.
CLEAR – outcomes: Statin intolerant with Vascular Disease or high risk factors (Diabetes, women over age 65, men over 60).
RL-1643: Studying Evinacumab, a monoclonal antibody agent binding to ANGPTL3.